Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Observational Studies

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    61 result(s) found for: Observational Studies. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2014-004827-29 Sponsor Protocol Number: VX14-661-110 Start Date*: 2015-09-01
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long term Treatment With VX 661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, ...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) AT (Completed) FR (Completed) DK (Completed) NL (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000842-16 Sponsor Protocol Number: PIRVACoV Start Date*: 2021-03-18
    Sponsor Name:Kristina Jakobsson
    Full Title: Does PFAS-exposure modify the risk of COVID-19 infection or the immunological response after vaccination against SARS-CoV-2?
    Medical condition: An observational study in healthy, differently PFAS-exposed subjects to check if PFAS modifies the immunological response to SARS-CoV-2 vaccination. The immunological response is quantified as SARS...
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004865 10084462 SARS-CoV-2 vaccination LLT
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005636-29 Sponsor Protocol Number: IDX-03YF Start Date*: 2013-05-17
    Sponsor Name:Idenix Pharmaceuticals, Inc.
    Full Title: 3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Act...
    Medical condition: Chronic Hepatitis C Infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001074-29 Sponsor Protocol Number: CLOU064A2201E1 Start Date*: 2019-10-10
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in CLOU064A2201
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) SK (Completed) FR (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001644-11 Sponsor Protocol Number: VX15-809-110 Start Date*: Information not available in EudraCT
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozy...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing) GB (Completed) BE (Completed) DK (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002945-36 Sponsor Protocol Number: TRA108132 Start Date*: 2007-03-12
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: LENS – Long-term Eltrombopag ObservatioNal Study - A long term observational ocular safety study in adults who have received study medication (SB-497115-GR / eltrombopag olamine or placebo) in a ph...
    Medical condition: Long-term ocular safety specifically related to cataract formation in subjects who have previously participated in a phase II or III protocol for eltrombopag (SB-497715-GR)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007739 Cataract LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) ES (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005667-34 Sponsor Protocol Number: G0701625 Start Date*: 2009-01-16
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Randomised Trial of Genetic Testing and Targeted Zoledronic acid therapy to Prevent SQSTM1 Mediated Paget's Disease (Zoledronate in the Prevention of Paget's).
    Medical condition: Paget's disease of the bone (PDB)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10033363 Paget's disease of bone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) IT (Ongoing) IE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-003303-38 Sponsor Protocol Number: EPI40670/WWE115682 Start Date*: 2011-10-13
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: Observational Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761
    Medical condition: HIV-1 infected adults
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000630-34 Sponsor Protocol Number: MLN0002-3029 Start Date*: 2022-12-09
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Intravenous in Pediatric Patients With Ulcerative Colitis or Crohn’s Disease
    Medical condition: Active Ulcerative Colitis (UC) or Crohn's disease (CD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Ongoing) PL (Ongoing) CZ (Ongoing) ES (Prematurely Ended) SK (Prematurely Ended) GR (Ongoing) BE (Ongoing) LT (Completed) HR (Ongoing) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-001369-28 Sponsor Protocol Number: 880 Start Date*: 2014-10-30
    Sponsor Name:Gateshead Health NHS Foundation Trust
    Full Title: THYRoxine in Acute Myocardial Infarction (ThyrAMI)
    Medical condition: Hypothyroidism and Acute Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003581-40 Sponsor Protocol Number: CRO1992 Start Date*: 2012-09-28
    Sponsor Name:Imperial College, Research Governance Manager
    Full Title: A prospective, observational study to examine the effects of ageing on the clinical outcomes of people living with HIV in England and Ireland.
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10000807 Acute HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000604-41 Sponsor Protocol Number: VX12-809-105 Start Date*: 2014-01-21
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygo...
    Medical condition: Cystic fibrosis in patients homozygous or heterozygous for the F508del-CFTR Mutation
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) SE (Completed) AT (Completed) BE (Completed) GB (Completed) DE (Completed) NL (Completed) ES (Completed) IE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-002549-12 Sponsor Protocol Number: A4091064 Start Date*: 2015-09-08
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, MULTICENTER, LONG-TERM OBSERVATIONAL STUDY OF SUBJECTS FROM TANEZUMAB STUDIES WHO UNDERGO A TOTAL KNEE, HIP OR SHOULDER REPLACEMENT
    Medical condition: Osteoarthritis of the hip or knee
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10023476 Knee osteoarthritis LLT
    18.1 100000004859 10020108 Hips osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) ES (Completed) BG (Completed) DE (Completed) PT (Completed) FI (Completed) GB (Completed) SE (Completed) LT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004753-87 Sponsor Protocol Number: BBI608-901 Start Date*: 2020-03-18
    Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc.
    Full Title: A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Sumitomo Dainippon Pharma Oncology, Inc. sponsored Napabucasin Protocols
    Medical condition: Metastatic Pancreatic Adenocarcinoma and Metastatic Colorectal Cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000903-41 Sponsor Protocol Number: A3921053 Start Date*: 2011-10-24
    Sponsor Name:Pfizer, S.L.U.
    Full Title: AN OBSERVATIONAL STUDY TO COLLECT FOLLOW-UP CLINICAL DATA FROM KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED TOFACITINIB (CP-690,550) IN COMPLETED PHASE 2 STUDIES
    Medical condition: KIDNEY TRANSPLANT
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003028-30 Sponsor Protocol Number: 808040019 Start Date*: 2015-11-02
    Sponsor Name:Technische Universität München, Fakultät für Medizin
    Full Title: Fr1da Insulin Intervention - Mechanistic study using oral insulin for immune and treatment efficacy in secondary prevention of type 1 diabetes
    Medical condition: Risk for type 1 diabetes
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004674-42 Sponsor Protocol Number: GS-US-334-1113 Start Date*: 2015-11-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
    Medical condition: Chronic Hepatitis C virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    20.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) PL (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-019102-17 Sponsor Protocol Number: Y-55-52120-147 Start Date*: Information not available in EudraCT
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A PHASE III, PROSPECTIVE, MULTICENTRE, OPEN LABEL, EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND EFFICACY OF REPEATED TREATMENT WITH DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN C...
    Medical condition: Lower limb spasticity in children with dynamic equinus foot deformity due to cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10024132 Leg spasticity LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006373-25 Sponsor Protocol Number: A3921029 Start Date*: 2007-03-23
    Sponsor Name:Pfizer, S.A.
    Full Title: ESTUDIO OBSERVACIONAL PROSPECTIVO PARA EVALUAR LA SEGURIDAD A LARGO PLAZO Y EL ESTADO FUNCIONAL DE SUJETOS CON ARTRITIS REUMATOIDE INCLUIDOS PREVIAMENTE EN ESTUDIOS DE CP-690,550 A PROSPECTIVE OBS...
    Medical condition: CP-690,550 se está desarrollando como fármaco antirreumático modificador de la enfermedad (FARME) para el tratamiento de la artritis reumatoide (AR). CP 690,550 is being developed as a disease mo...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) SE (Completed) SK (Completed) CZ (Completed) GR (Completed) DE (Completed) FI (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002243-25 Sponsor Protocol Number: CAAE581A2203E2 Start Date*: 2007-08-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis
    Medical condition: Osteoporosis
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) FR (Completed) AT (Completed) ES (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:38:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA